RedChip

Rail Vision is at the forefront of an evolution in train safety. The braking distance for trains is often substantially longer than a train driver’s visual capacity, leading to accidents that result in needless loss of life and significant and costly interruptions to key infrastructure corridors. Through advanced, long-range A.I. detection systems, Rail Vision provides unparalleled obstacle identification on and near tracks, a key enabling technology for the future of autonomous train operations. Rio Tinto, one of the world’s largest mining companies, is currently testing the company’s technology on its autonomous mining trains in Australia, and Knorr Bremse, a 110-year-old company and the world’s leader in train braking technology is a key strategic investor in Rail Vision, having invested $25M across two investment cycles. The Company recently announced a 10-unit sales agreement with Israel Railways and a leading rail and rail leasing services company purchased a Rail Vision switch yard system in Q1 2023 for a proof of concept that is expected to lead to a large purchase order in 2H23. To learn more, visit: https://bit.ly/RVSNStockInfo #RailSafety #AIDetection

Everything Blockchain is disrupting the $89 billion (2022) global enterprise data management market with a multi-pronged growth strategy that offers real-world data solutions that add value for business customers through speed, security, and efficiency. With 25 patents issued or pending globally and a highly accomplished management team including cybersecurity pioneer Toney Jennings as CEO, Everything Blockchain is positioned to take advantage of the rapidly growing demand for enterprise data storage, management, and protection solutions, providing a superior offering when compared to solutions from multi-billion-dollar competitors. According to Grand View Research, the global enterprise data management market is expected to grow at a 12.1% CAGR through 2030, reaching $222 billion. As Everything Blockchain capitalizes on this massive opportunity, it is committed to uplisting to a senior exchange in FY24 (ending Jan. 31, 2024), continuing to pursue strategic acquisition opportunities, signing new household-name clients, and adding key personnel in order to further the development of its proprietary enterprise data solutions. As such, investors should consider Everything Blockchain as an attractive option for long-term growth potential backed by strong market tailwinds. Learn more at: https://bit.ly/EverythingBlockchain

Reviva (NASDAQ: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries. To learn more, visit: https://bit.ly/3YAo2Vr Transcription: Estimated that more than one in five U.S. adults live with a mental illness (57.8 million in 2021) Introducing Reviva Pharmaceuticals (Nasdaq: RVPH) Reviva's lead drug Brilaroxazine is expecting efficacy results for schizophrenia this year 2023! Does Brilaroxazine become a beacon of hope everyone suffering from: Bipolar Disorder TAM: $5.4 Billion Major Depressive TAM: $15.9 Billion Schizophrenia TAM: $7.9 Billion ADHD TAM: $24.9 Billion Idiopathic Pulmonary Fibrosis TAM: $5.9Billion

INNO Holdings is transforming the construction industry with its innovative approach to sustainable, efficient, and cost-effective building methods. Utilizing advanced steel-framing technology, the Company's solutions reduce construction times by over 50% while significantly cutting labor costs. INNO Holdings manufactures metal studs, prefab wall panels, joists, and trusses offsite, delivering assembled products ready for erection and connection. This approach results in cleaner, more organized construction sites with fewer safety hazards. As a trailblazer in the burgeoning $235.4 billion offsite construction market, INNO Holdings is seizing the opportunity presented by the increasing trend toward modular building techniques. With tailwinds from President Biden’s Executive Order 14057 and the Los Angeles City Council's recent ban on wood-frame buildings, there is a growing demand for INNO's products. The Company isn't merely offering an alternative to traditional construction methods; it's establishing a new industry standard and delivering unparalleled value to its commercial, residential, and industrial clients. With upcoming product launches and an existing order backlog exceeding $15 million, INNO Holdings appears to be on the cusp of substantial growth. Learn more at: https://bit.ly/3uTKVID

Rail Vision is at the forefront of an evolution in train safety. The braking distance for trains is often substantially longer than a train driver’s visual capacity, leading to accidents that result in needless loss of life and significant and costly interruptions to key infrastructure corridors. Through advanced, long-range A.I. detection systems, Rail Vision provides unparalleled obstacle identification on and near tracks, a key enabling technology for the future of autonomous train operations. Rio Tinto, one of the world’s largest mining companies, is currently testing the company’s technology on its autonomous mining trains in Australia, and Knorr Bremse, a 110-year-old company and the world’s leader in train braking technology is a key strategic investor in Rail Vision, having invested $25M across two investment cycles. The Company recently announced a 10-unit sales agreement with Israel Railways and a leading rail and rail leasing services company purchased a Rail Vision switch yard system in Q1 2023 for a proof of concept that is expected to lead to a large purchase order in 2H23. To learn more, visit: https://bit.ly/RVSNStockInfo Learn more at RedChip.com

INNO Holdings is transforming the construction industry with its innovative approach to sustainable, efficient, and cost-effective building methods. Utilizing advanced steel-framing technology, the Company's solutions reduce construction times by over 50% while significantly cutting labor costs. INNO Holdings manufactures metal studs, prefab wall panels, joists, and trusses offsite, delivering assembled products ready for erection and connection. This approach results in cleaner, more organized construction sites with fewer safety hazards. As a trailblazer in the burgeoning $235.4 billion offsite construction market, INNO Holdings is seizing the opportunity presented by the increasing trend toward modular building techniques. With tailwinds from President Biden’s Executive Order 14057 and the Los Angeles City Council's recent ban on wood-frame buildings, there is a growing demand for INNO's products. The Company isn't merely offering an alternative to traditional construction methods; it's establishing a new industry standard and delivering unparalleled value to its commercial, residential, and industrial clients. With upcoming product launches and an existing order backlog exceeding $15 million, INNO Holdings appears to be on the cusp of substantial growth. Learn more at: https://bit.ly/3uTKVID

Mobilicom provides cybersecurity and robust solutions for drones and robotics. The Company is positioned to capture market leadership as the top end-to-end provider of hardware and software solutions in the rapidly growing defense and commercial drone and robotics market, a total addressable market expected to reach $8.5 billion by 2026. The Ukraine-Russia conflict is expected to further drive demand for Mobilicom’s drone cybertech solutions. The Company’s large portfolio of field-proven technologies includes cybersecurity, software, and hardware solutions that power, connect, guide, and secure drones and robotics. Through deployments across 16 countries with over 50 customers, Mobilicom generates revenues from hardware and software sales, licensing fees, and professional support services. Its IP strategy includes patents and more often, trade secrets, in accordance with top-secret military applications. Mobilicom’s customers include the world’s leading defense and commercial drone manufacturers. Visit bit.ly/46iJVux to learn more.

BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites. BioVie is poised for significant catalysts in 2023, including data read out from its Alzheimer’s Phase 3 trial, expected in Q4 2023, as well as interim data read outs from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. https://bit.ly/BioVie

Royalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces to obtain an ongoing royalty or cashflow stream in the project. Royalty Management finds undervalued assets that are either underutilized, undeveloped or at an inflection point in their life cycle. The Company targets three primary sectors of investment: Resources & Land Assets, Recurring Use Assets, IP & Digital Assets. Visit RMCOinfo.com to learn more! bit.ly/3FQhAku

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Royalty Management (NASDAQ: RMCO) and Mobilicom Limited (NASDAQ: MOB). Explore the latest insights and updates in the world of small-cap stocks. Visit RedChip.com to learn more and watch the episode: https://bit.ly/3PSQ63t.

Mobilicom provides cybersecurity and robust solutions for drones and robotics. The Company is positioned to capture market leadership as the top end-to-end provider of hardware and software solutions in the rapidly growing defense and commercial drone and robotics market, a total addressable market expected to reach $8.5 billion by 2026. The Ukraine-Russia conflict is expected to further drive demand for Mobilicom’s drone cybertech solutions. The Company’s large portfolio of field-proven technologies includes cybersecurity, software, and hardware solutions that power, connect, guide, and secure drones and robotics. Through deployments across 16 countries with over 50 customers, Mobilicom generates revenues from hardware and software sales, licensing fees, and professional support services. Its IP strategy includes patents and more often, trade secrets, in accordance with top-secret military applications. Mobilicom’s customers include the world’s leading defense and commercial drone manufacturers. Visit bit.ly/46iJVux to learn more.

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Royalty Management (NASDAQ: RMCO) and ASP Isotopes (NASDAQ: ASPI). Explore the latest insights and updates in the world of small-cap stocks. Visit RedChip.com to learn more and watch the episode: https://bit.ly/3PSQ63t.

bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD’s purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company’s flow cytometry platform, enhanced by AI-driven automated data analysis, is also being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis and treatment. Visit bit.ly/49vYFJr to learn more.

Royalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces in order to obtain an ongoing royalty or cashflow stream in the project. RMCO finds undervalued assets that are either under utilized, undeveloped or at an inflection point in their life cycle. Visit RMCOinfo.com to learn more. bit.ly/3FQhAku 0:00 - Start 0:10 - Company Overview 1:30 - Alternative Capital Solutions 2:30 - Investment Approach 4:05 - Market Opportunity 5:50 - Business Model 7:45 - Management Team 9:39 - Value Propposition

Royalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces in order to obtain an ongoing royalty or cashflow stream in the project. RMC finds undervalued assets that are either under utilized, undeveloped or at an inflection point in their life cycle. Visit RMCOinfo.com to learn more. bit.ly/3FQhAku

Royalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces in order to obtain an ongoing royalty or cashflow stream in the project. RMC finds undervalued assets that are either under utilized, undeveloped or at an inflection point in their life cycle. Visit LINK to learn more.

Royalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces in order to obtain an ongoing royalty or cashflow stream in the project. RMCO finds undervalued assets that are either under utilized, undeveloped or at an inflection point in their life cycle. Visit RMCOinfo.com to learn more. bit.ly/3FQhAku 0:00 - Start 0:10 - Company Overview 1:30 - Alternative Capital Solutions 2:30 - Investment Approach 4:05 - Market Opportunity 5:50 - Business Model 7:45 - Management Team 9:39 - Value Propposition

bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. Visit BIAFinfo.com to learn more. bit.ly/3FyiPEQ

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from DevvStream (OCTQB: DSTRF) and BioVie (NASDAQ: BIVI). Explore the latest insights and updates in the world of small-cap stocks. Visit RedChip.com to learn more and watch the episode: https://bit.ly/3PSQ63t.

BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) and BIV201 for Refractory Ascites and HRS-AKI. Visit https://bit.ly/BioVie to learn more.

DevvStream Holdings Inc. (OTC: DSTRF), a pioneer in carbon streaming, was established in 2021. DevvStream specializes in cutting-edge technology-driven decarbonization solutions, empowering the growth and monetization of environmental assets. Discover their innovative environmental solutions at www.devvstream.com. Learn how DevvStream is shaping a greener future. Visit https://bit.ly/3Mgru2i to learn more. 0:00 - Start 0:15 - Overview of DevvStream 1:22 - NASDAQ Uplisting 2:30 - Market Opportunity 4:03 - Business Model 5:40 - Management Team 7:15 - Value Proposition

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from SPI Energy (NASDAQ: SPI) and Bullfrog AI (NASDAQ: BFRG). Explore the latest insights and updates in the world of small-cap stocks. Visit RedChip.com to learn more and watch the episode: https://bit.ly/3PSQ63t.

This week’s episode of the RedChip Money Report includes interviews with senior executives from ASP Isotopes (NASDAQ: ASPI) & Bullfrog AI (NASDAQ: BFRG). Visit RedChip.com to learn more. https://bit.ly/3PSQ63t

ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Visit https://www.redchip.com/stocks/ASPI to learn more. https://bit.ly/ASPIinfo

SPI Energy is a global renewable energy company headquartered in McClellan Park, California, with three core divisions: SolarJuice (residential and commercial solar solutions), SPI Solar and Orange Power (commercial and utility solar services), and EdisonFuture (EV and green hydrogen technology). They operate worldwide and are expanding into emerging green energy sectors like battery storage and EV charging stations.